Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Cell Line, Tumor: A cell line derived from cultured tumor cells.Molecular Targeted Therapy: Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.Drug Delivery Systems: Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.Drug Design: The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Breast Neoplasms: Tumors or cancer of the human BREAST.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Nanomedicine: The branch of medicine concerned with the application of NANOTECHNOLOGY to the prevention and treatment of disease. It involves the monitoring, repair, construction, and control of human biological systems at the molecular level, using engineered nanodevices and NANOSTRUCTURES. (From Freitas Jr., Nanomedicine, vol 1, 1999).Drug Discovery: The process of finding chemicals for potential therapeutic use.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Early Detection of Cancer: Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Protein Kinase Inhibitors: Agents that inhibit PROTEIN KINASES.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Nanoparticles: Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging.Drug Screening Assays, Antitumor: Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Lung Neoplasms: Tumors or cancer of the LUNG.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Models, Biological: Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.Therapeutics: Procedures concerned with the remedial treatment or prevention of diseases.Small Molecule Libraries: Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or other chemical interactions.Enzyme Inhibitors: Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.RNA Interference: A gene silencing phenomenon whereby specific dsRNAs (RNA, DOUBLE-STRANDED) trigger the degradation of homologous mRNA (RNA, MESSENGER). The specific dsRNAs are processed into SMALL INTERFERING RNA (siRNA) which serves as a guide for cleavage of the homologous mRNA in the RNA-INDUCED SILENCING COMPLEX. DNA METHYLATION may also be triggered during this process.Inhibitor of Apoptosis Proteins: A conserved class of proteins that control APOPTOSIS in both VERTEBRATES and INVERTEBRATES. IAP proteins interact with and inhibit CASPASES, and they function as ANTI-APOPTOTIC PROTEINS. The protein class is defined by an approximately 80-amino acid motif called the baculoviral inhibitor of apoptosis repeat.Drug Evaluation, Preclinical: Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.HCT116 Cells: Human COLORECTAL CARCINOMA cell line.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Transplantation, Heterologous: Transplantation between animals of different species.Inhibitory Concentration 50: The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Colonic Neoplasms: Tumors or cancer of the COLON.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Stomach Neoplasms: Tumors or cancer of the STOMACH.Histone Deacetylase Inhibitors: Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Mice, SCID: Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Receptor, Epidermal Growth Factor: A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Genetic Therapy: Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.HSP90 Heat-Shock Proteins: A class of MOLECULAR CHAPERONES whose members act in the mechanism of SIGNAL TRANSDUCTION by STEROID RECEPTORS.Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Pharmacy and Therapeutics Committee: An advisory group composed primarily of staff physicians and the pharmacist which serves as the communication link between the medical staff and the pharmacy department.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Benzamides: BENZOIC ACID amides.Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Protein Binding: The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.DNA Damage: Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.PiperazinesProto-Oncogene Proteins c-bcl-2: Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.Peptides: Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.Phosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.Protein Structure, Tertiary: The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Protein-Serine-Threonine Kinases: A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Genetic Predisposition to Disease: A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.National Cancer Institute (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Models, Molecular: Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.HeLa Cells: The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for VIRUS CULTIVATION and antitumor drug screening assays.Pharmacology, Clinical: The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.Risk: The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Structure-Activity Relationship: The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Receptors, Estrogen: Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.United StatesRegistries: The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Binding Sites: The parts of a macromolecule that directly participate in its specific combination with another molecule.Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Survivors: Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.Medical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.Rectal Neoplasms: Tumors or cancer of the RECTUM.Neoplastic Stem Cells: Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.DNA, Neoplasm: DNA present in neoplastic tissue.DNA Methylation: Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.MicroRNAs: Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.Prostate-Specific Antigen: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Odds Ratio: The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.Antineoplastic Agents, Phytogenic: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.Oligonucleotide Array Sequence Analysis: Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.Tamoxifen: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Smoking: Inhaling and exhaling the smoke of burning TOBACCO.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
"Molecular Cancer Therapeutics. 14 (10): 2215-27. doi:10.1158/1535-7163.MCT-15-0419. PMC 4596774 . PMID 26206334.. ... Cdc42 is overexpressed in non-small cell lung cancer, colorectal adenocarcinoma, melanoma, breast cancer, and testicular cancer ... The small molecular inhibitor AZA197 has been used to inhibit Cdc42 in the treatment of KRAS mutant colorectal cancers.[11] ... Role in cancer[edit]. Recently, Cdc42 has been shown to actively assist in cancer progression. Several studies have established ...
"Molecular Cancer Therapeutics. 7 (11): 3546-55. doi:10.1158/1535-7163.MCT-08-0569. PMID 19001437.. ... Recently it has been described a GLUT1 inhibitor, DERL3, that is often methylated in colorectal cancer. In this cancer, DERL3 ... "Molecular Biology of the Cell. 10 (4): 819-32. doi:10.1091/mbc.10.4.819. PMC 25204. PMID 10198040.. ... "Molecular Aspects of Medicine. 34 (2-3): 121-38. doi:10.1016/j.mam.2012.07.001. PMC 4104978. PMID 23506862.. ...
... as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer". Molecular Cancer Therapeutics ... "Molecular and Cellular Biology. 20 (18): 6872-81. doi:10.1128/MCB.20.18.6872-6881.2000. PMC 86228. PMID 10958683.. ... Molecular and Cellular Biology. 21 (14): 4544-52. doi:10.1128/MCB.21.14.4544-4552.2001. PMC 87113. PMID 11416133.. ... "Molecular and Cellular Biology. 16 (9): 4869-78. doi:10.1128/mcb.16.9.4869. PMC 231489. PMID 8756646.. ...
"Molecular Cancer Therapeutics. 13 (4): 833-841. doi:10.1158/1535-7163.MCT-13-0688. ISSN 1535-7163. PMID 24482381.. ...
"Molecular Cancer Therapeutics. 10 (3): 395-403. doi:10.1158/1535-7163.MCT-10-0905. PMC 3413411. PMID 21216931.. ... Rapamycin has shown to induce cancer cell death by stimulating autophagy or apoptosis, but the molecular mechanism of apoptosis ... A better understanding of the molecular mechanisms that are involved in the response of cancer cells to mTOR inhibitors are ... This study enrolled patients being treated for HER2-amplified breast cancer, HER2-mutant non-small-cell lung cancer, and other ...
Jensen EV, Jordan VC (Jun 2003). "The estrogen receptor: a model for molecular medicine". Clinical Cancer Research. 9 (6): 1980 ... Nilsson S, Koehler KF, Gustafsson JÅ (Oct 2011). "Development of subtype-selective oestrogen receptor-based therapeutics". ... AACR Cancer Concepts Factsheet on SERMs STAR: a head-to-head comparison of tamoxifen and raloxifene as breast-cancer ... Tamoxifen is a first-line hormonal treatment of ER-positive metastatic breast cancer. It is used for breast cancer risk ...
Molecular Cancer Therapeutics. 6 (9): 2409-17. doi:10.1158/1535-7163.MCT-07-0156. PMID 17876040. Gullbo, J; Lindhagen, E; ... Wickström, M; Larsson, R; Nygren, P; Gullbo, J (2011). "Aminopeptidase N (CD13) as a target for cancer chemotherapy". Cancer ... Aminopeptidase N is frequently overexpressed in tumors and has been associated with the growth of different human cancers ... A preclinical study, performed at Dana-Farber Cancer Institute, demonstrated that melflufen induced apoptosis in multiple ...
Molecular Cancer Therapeutics. 4 (7): 1086-1095. doi:10.1158/1535-7163.MCT-04-0345. PMID 16020666. ... Cancer Research. 61 (3): 1013-1021. PMID 11221827. Yu, Melvin J.; Kishi, Yoshito; Littlefield, Bruce A. (2005). "Discovery of ... has become an important chemotherapy treatment for certain types of cancer. van Soest, R. (2014). Van Soest RW, Boury-Esnault N ...
Molecular cancer therapeutics. 9 (11): 2914-23. doi:10.1158/1535-7163.MCT-10-0552. PMC 2978777 . PMID 20978163. Yang, Hailing; ... The second class is composed of MAPs with a molecular weight of 200-1000 kDa, of which there are four known types: MAP-1, MAP-2 ... Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. The Self-Assembly and Dynamic Structure of ... The α and β-tubulin subunits are approximately 50% identical at the amino acid level, and each have a molecular weight of ...
Molecular Cancer Therapeutics. 1 (8): 639-49. PMID 12479224. Janion, C. (2001). "Some aspects of the SOS response system-a ... and this contributes to progression to endometrial cancer, BRCA-mutated ovarian cancer, and BRCA-mutated serous ovarian cancer ... 2002). "The Preventable Causes of Cancer". Molecular biology of the cell (4th ed.). New York: Garland Science. ISBN 0-8153-4072 ... Modern cancer treatments attempt to localize the DNA damage to cells and tissues only associated with cancer, either by ...
Molecular Cancer Therapeutics. 6 (1): 262-8. doi:10.1158/1535-7163.MCT-06-0542. PMID 17237285. Ewing RM, Chu P, Elisma F, Li H ... UPS proteolysis plays a major role in responses of cancer cells to stimulatory signals that are critical for the development of ... Gödderz D, Dohmen RJ (Feb 2009). "Hsm3/S5b joins the ranks of 26S proteasome assembly chaperones". Molecular Cell. 33 (4): 415- ... Adams J (Apr 2003). "Potential for proteasome inhibition in the treatment of cancer". Drug Discovery Today. 8 (7): 307-15. doi: ...
Molecular Cancer Therapeutics. 9 (5): 1219-1233. doi:10.1158/1535-7163.MCT-09-0683. PMC 2875164 . PMID 20457619. Okui, T; Shimo ... "Structure-based design of cancer therapeutics" (PDF). The Institute of Cancer Research. "AUY922". Vernalis. Archived from the ... a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models". Breast Cancer Research. ... Luminespib (INN, previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer. It was ...
Molecular Cancer Therapeutics. 13 (7): 1690-703. doi:10.1158/1535-7163.MCT-13-0868. PMC 4373557 . PMID 24688051. ... Leelamine has been shown to be effective against certain cancer cells, independent from its activity on Cannabinoids or PDK1. ... US patent 3454626 US patent 4559178 Kuzu, O. F.; Gowda, R.; Sharma, A.; Robertson, G. P. (2014). "Leelamine Mediates Cancer ...
Molecular Cancer Therapeutics. 8 (1): 10-16. doi:10.1158/1535-7163.MCT-08-0840. PMC 2651829 . The Diseases of Occupations, ... such as skin cancer caused by excessive exposure to ultraviolet radiation in sunlight Disease caused by exposure to toxic or ...
Molecular cancer therapeutics. 8 (8): 2424-31. doi:10.1158/1535-7163.mct-08-0938. PMC 2735101 . PMID 19671745. Eloranta, JJ; ... Biology and therapeutic applications to cancer". Cancer biology & therapy. 13 (14): 1355-73. doi:10.4161/cbt.22020. PMC 3542225 ... The molecular basis for HFM was established in 2006 with the identification of the proton-coupled folate transporter (PCFT) as ... Grapp, M; Just, IA; Linnankivi, T; Wolf, P; Lücke, T; Häusler, M; Gärtner, J; Steinfeld, R (July 2012). "Molecular ...
Molecular Cancer Therapeutics. 9 (2): 379-88. doi:10.1158/1535-7163.MCT-09-0650. PMID 20124460. GeneReviews/NCBI/NIH/UW entry ... Molecular Pharmacology. 62 (1): 65-74. doi:10.1124/mol.62.1.65. PMID 12065756. Olivieri C, Mira E, Delù G, Pagella F, Zambelli ... Human Molecular Genetics. 9 (8): 1227-37. doi:10.1093/hmg/9.8.1227. PMID 10767348. Kjeldsen AD, Brusgaard K, Poulsen L, Kruse T ... Molecular Pharmacology. 62 (1): 58-64. doi:10.1124/mol.62.1.58. PMID 12065755. Attisano L, Cárcamo J, Ventura F, Weis FM, ...
Molecular Cancer Therapeutics. 13 (10): 2384-98. doi:10.1158/1535-7163.MCT-14-0172. PMC 4185238 . PMID 25103559. Liu, J; Qin, ... "OSU-03012 interacts with lapatinib to kill brain cancer cells". Cancer Biology and Therapy. 13 (14): 1501-11. doi:10.4161/cbt. ... Arno Therapeutics Inc receives european orphan drug designation for AR-12 to reat two infectious diseases. Reuters, 30 Apr 2015 ... Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration. Journal of ...
Reactivating Rb in cancer". Molecular Cancer Therapeutics. 12 (11_Supplement): PR02. doi:10.1158/1535-7163.TARG-13-PR02. Sosman ... Many cancer cells have shown abnormalities that increase the activity of CDK, leading to the inactivation of certain tumor ... In other words, cancer's development of drug resistance can be mitigated with the addition of ribociclib to the therapeutic ... It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex ...
Molecular Cancer Therapeutics. 13 (8): 2004-17. doi:10.1158/1535-7163.mct-13-0964. PMID 24994771. Chen TC, Cho HY, Wang W, ... Molecular Cancer Therapeutics. 13 (5): 1181-93. doi:10.1158/1535-7163.mct-13-0882. PMID 24623736. Ueno T, Ko SH, Grubbs E, ... Molecular Cancer Therapeutics. 5 (3): 732-8. doi:10.1158/1535-7163.MCT-05-0098. PMID 16546988. Quinn JA, Jiang SX, Reardon DA, ... European Organisation for Research Treatment of Cancer Brain Tumour Radiation Oncology Groups, National Cancer Institute of ...
Molecular Cancer Therapeutics. 15: 1859-1869. doi:10.1158/1535-7163.MCT-16-0025. Botham RC, Roth HS, Book AP, Roady PJ, Fan TM ... Cancer cell 'executioner' found. BBC News 27 August 2006. Cancer cells 'can live forever'. BBC News 29 April 2004. Vanquish ... liver and gallbladder cancer xenografts". Molecular Oncology. 8 (8): 1640-1652. doi:10.1016/j.molonc.2014.06.015. Patel V, ... and liver cancers, procaspase-3 is present in higher concentrations. For instance, lung cancer cells can have over 1000 times ...
Molecular cancer therapeutics. 9 (4): 920-8. doi:10.1158/1535-7163.MCT-09-1071. PMID 20354122. Tung, SY; Hong, JY; Walz, T; ... Cellular and molecular life sciences : CMLS. 69 (4): 641-50. doi:10.1007/s00018-011-0771-x. PMC 3266462 . PMID 21796450. ... to discover novel interactions and aid in characterizing the molecular mechanisms through which small molecules affect the ...
Molecular Cancer Therapeutics. 14: 1868-76. doi:10.1158/1535-7163.MCT-15-0188. PMID 26089370. ... "Tumor-associated antigen L6 and the invasion of human lung cancer cells". Clinical Cancer Research. 9 (7): 2807-16. PMID ... Storim J, Friedl P, Schaefer BM, Bechtel M, Wallich R, Kramer MD, Reinartz J (Jul 2001). "Molecular and functional ... International Journal of Cancer. 116 (2): 243-52. doi:10.1002/ijc.21089. PMID 15812828. Stelzl U, Worm U, Lalowski M, Haenig C ...
Molecular Cancer Therapeutics. 12 (4): 416-26. doi:10.1158/1535-7163.MCT-12-0731. PMC 3624043 . PMID 23371858. Li N, Fu H, ... Plant Molecular Biology. 87 (4-5): 355-69. doi:10.1007/s11103-015-0282-5. PMID 25648551. "Nanobodies herald a new era in cancer ... The comparatively low molecular mass leads to a better permeability in tissues, and to a short plasma half-life since they are ... With a molecular weight of only 12-15 kDa, single-domain antibodies are much smaller than common antibodies (150-160 kDa) which ...
Molecular Cancer Therapeutics. 12 (4): 471-80. doi:10.1158/1535-7163.MCT-12-0904. PMID 23416275. Jiang W, Wang S, Xiao M, Lin Y ... Molecular Cancer Research. 12 (9): 1244-53. doi:10.1158/1541-7786.MCR-14-0223-T. PMC 4163538 . PMID 24866770. Xu Y, Li F, Lv L ... Cancer Cell. 20 (4): 487-99. doi:10.1016/j.ccr.2011.09.004. PMC 3199577 . PMID 22014574. Jing H, Hu J, He B, Negrón Abril YL, ... Cancer Cell. 29 (5): 767-68. doi:10.1016/j.ccell.2016.04.005. PMID 27165747. Xu SN, Wang TS, Li X, Wang YP (Sep 2016). "SIRT2 ...
Molecular Cancer Therapeutics. 2 (5): 427-36. PMID 12748304. Molad, Yair (2002). "Update on colchicine and its mechanism of ... Molecular Cancer Therapeutics. 8 (8): 2086-95. doi:10.1158/1535-7163.MCT-09-0366. PMID 19671735. Islam, Mohd.; Iskander, Magdy ... Vinblastine is mainly useful for treating Hodgkin's lymphoma, advanced testicular cancer and advanced breast cancer. ... Cancer can develop the resistance by mutations to their cells which result in alterations in the surface of cells or in ...
... and certain cancers such as glucagonomas.[44] Individuals with cancer may be at a higher risk of mortality if they also have ... Sun T, Han X (2019). "Death versus dedifferentiation: The molecular bases of beta cell mass reduction in type 2 diabetes". ... Therapeutics. 22 Suppl 2: 16-9. doi:10.1111/j.1365-2036.2005.02588.x. PMID 16225465.. ... The Journal of Steroid Biochemistry and Molecular Biology. 114 (1-2): 40-3. doi:10.1016/j.jsbmb.2008.12.022. PMID 19444934.. ...
Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res. 2012;18(16):4234-9. ... cancer. Adv Drug Deliv Rev. 2013;65(13-14):1748-62. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer ... human cancer cells. Four human cancer cells lines were used: uterus sarcoma, colon cancer, colon adenocarcinoma, and breast ... The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010;70( ...
... is a specialty section of Frontiers in Oncology and Frontiers in Pharmacology. ... Cancer Molecular Targets and Therapeutics welcomes submissions of the following article types: Book Review, Case Report, ... All manuscripts must be submitted directly to the section Cancer Molecular Targets and Therapeutics, where they are peer- ... Articles published in the section Cancer Molecular Targets and Therapeutics will benefit from the Frontiers impact and tiering ...
Copyright 2016 by the American Association for Cancer Research.. Molecular Cancer Therapeutics. eISSN: 1538-8514. ISSN: 1535- ... Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Chan et al. Mol Cancer Ther 2017 16 ... Purchase Access to all of Mol Cancer Ther for 1 day for US$50.00. Email: required ...
... you want to study the molecular pathology, biology and therapeutics of cancer at an advanced level and develop a dynamic career ... Course Cancer Molecular Pathology and Therapeutics Qualification MSc Duration 1 year full-time Start Dates September each year ... This is for you if... you want to study the molecular pathology, biology and therapeutics of cancer at an advanced level and ... Monitoring the circulating cancer genome for patient follow up *Molecular characterisation of sputum from lung cancer patients ...
Copyright © 2020 by the American Association for Cancer Research.. Molecular Cancer Therapeutics. eISSN: 1538-8514. ISSN: 1535- ... Small Molecule Therapeutics , AuthorChoice Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell ... Cancer Biology and Translational Studies A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via ... Large Molecule Therapeutics Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody-drug Conjugate ( ...
... which play an essential role in cancer metastasis. Overexpression... ... Neoexpression of N-cadherin in E-cadherin positive colon cancers. Int J Cancer. 2004;111:711-9.PubMedCrossRefGoogle Scholar ... Recently, targeting Twist has gained significant interests in cancer therapeutics. The inactivation of Twist by small RNA ... Twist also protects cancer cells from apoptotic cell death. In addition, Twist is responsible for the stemness of cancer cells ...
The Cancer Molecular Therapeutics Research Association (CMTRA) was created in 2008 to organize and host the annual Molecular ... The 2018 Molecular Therapeutics of Cancer Research meeting will be the eleventh annual conference sponsored by the CMTRA. ... Molecular Therapeutics of Cancer Research Conference 2018 Sunday, July 22, 2018 - Thursday, July 26, 2018 ... Therapeutics of Cancer Research meeting. The meeting objective is to provide a forum for presentation and discussion of ...
Cancer Research Online ISSN: 1538-7445. Cancer Research Print ISSN: 0008-5472. Journal of Cancer Research ISSN: 0099-7013. ... Abstract LB-310: PYK2 as a therapeutic target for pancreatic cancer Jing Hu, Chenxi Gao, Guangming Chen, Xuan Gao, Dennis H. ... Cancer Research Apr 2010, 70 (8 Supplement) SY14-03; DOI: 10.1158/1538-7445.AM10-SY14-03 ... Cancer Research Apr 2010, 70 (8 Supplement) SY18-01; DOI: 10.1158/1538-7445.AM10-SY18-01 ...
Ion channels are mainly located in the plasma membrane and thus serve crucial molecular mechanisms that transduce extracellular ... such as endothelial cells that form new blood vessels to support cancer cell proliferation and migration, anti-tumour or tumour ... There is a growing interest in ion channels as attractive cancer biomarkers as well as therapeutic targets to treat cancers.. ... in cancer cell migration, angiogenesis and metastatic spreading, and in cancer stem cell properties; role of ion channels in ...
... and related cancers. The journal welcomes submissions on the physiology, pathophysiology, etiology, diagnosis, and therapy of ... 2Gastroesophageal Cancer Therapeutics Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein ... From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal ... Recently the Cancer Genome Atlas Research Network has proposed four subtypes of gastric cancer dividing tumors into those ...
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date on all of the industrys business, science and regulatory news -- mergers and collaborations, FDA hearings and results, breakthroughs in research and much more.
Cancer Research Online ISSN: 1538-7445. Cancer Research Print ISSN: 0008-5472. Journal of Cancer Research ISSN: 0099-7013. ... More articles from Experimental and Molecular Therapeutics 11: Therapeutic Agents Targeting Signaling Components. ... Sensitization of tumor necrosis factor-induced lung cancer cell eath by luteolin Wei Ju, Xia Wang, Jordan J. Renouard, Yong Lin ... The NF-kB inhibitors curcumin and DHMEQ exert antitumor synergy with cisplatin in hepatic cancer cells. Analysis of ...
Department of Molecular Pharmacology and Cancer Therapeutics at Roswell Park Cancer Institute at University at Buffalo, the ... Department of Molecular Pharmacology and Cancer Therapeutics at Roswell Park Cancer Institute. Buffalo, NY ... Your submission to Department of Molecular Pharmacology and Cancer Therapeutics at Roswell Park Cancer Institute has been sent ... Your submission to Department of Molecular Pharmacology and Cancer Therapeutics at Roswell Park Cancer Institute has been sent ...
22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a ... ... Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Globe ... accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ... About Harpoon Therapeutics. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell ...
Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ... for oral presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, ... Kura Oncology Kura precision medicine tipifarnib HRAS head and neck cancer farnesyl transferase inhibitor HNSCC ... The data are embargoed until the beginning of the Spotlight on Proffered Papers 3: Targeting RAS Mutant Cancers session at 11: ...
Molecular,Targets,and,Cancer,Therapeutics,Conference,medicine,advanced medical technology,medical laboratory technology, ... Molecular and cellular effects of AP5346 a novelDA...,Access,Pharmaceuticals,to,Present,Data,on,ProLindac(TM),at,the,AACR-NCI- ... Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ... "International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications" taking place ...
download Molecular Climate someone is learning not, Thinking honest amplifiers, looking for greater surge scenario and poor ... 1,02 download Molecular Cancer Therapeutics: Strategies for In a 2016 envelope of the urban physical extension, the g of The ... Your download Molecular Cancer Therapeutics: is to handle Carolina a invalid fidelity time, Aristotelic in structure and media ... download Molecular Cancer Therapeutics: Strategies for Drug Through campaign to the coral in the Works of Emmanuel Levinas, " ...
CCR Molecular Pathways Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on ... Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on Hedgehog Signaling ... Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on Hedgehog Signaling ... Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on Hedgehog Signaling ...
... at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, on November 29, 2016, in Munich, Germany. ... The poster, to be presented at the upcoming EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, describes ... Poster Presentation at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium Monday, 21 November 2016 14: ... at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, on November 29, 2016, in Munich, Germany. ...
A novel cancer therapeutics with gene medicine and molecular targeted agents directing the p53 pathways in esophageal carcinoma ... Presentation] Immune response to tumor antigen, RalA, in patients with gastrointestinal cancers.2014. *. Author(s). 島田英昭、谷島聡、小池 ... In contrast, molecular targeted agents which stabilize the wild-type p53 in the terms of ubiquitination or functionally convert ... Journal Article] Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer.2017. *. ...
SOURCE: BC Cancer announces new Molecular Imaging and Therapeutics program thanks to $18 million donation ( ) Page printed: . ... BC Cancer announces new Molecular Imaging and Therapeutics program thanks to $18 million donation 25/10/2018 A new form of ... BC Cancer announces new Molecular Imaging and Therapeutics programCurrently selected. *BC Childrens Hospital shares tips to ... s history and will fuel a world-leading Molecular Imaging and Therapeutics program at BC Cancer spanning research and ...
fsn0503 poster at Molecular Targets & Cancer Therapeutics conference. Posted on 12th September 2013. 15th March 2019. ... Our Fsn0503 poster will be displayed at this years International Conference on Molecular Targets and Cancer Therapeutics Our ... ... AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. http:// ...
Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.. ... Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics. ... Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics. ... Lung cancer is a deadly disease that is difficult to diagnose and even more difficult to treat effectively. Many pathways are ...
Life Sciences with Mass General Cancer Center. Apply Today. ... Fellowship in Cancer Molecular Genetics and Therapeutics in ... Harvard/Mass General Postdoctoral Fellowship in Cancer Molecular Genetics and Therapeutics. Employer Mass General Cancer Center ... Topics of major interest include the p53 family of transcription factors, hereditary breast cancer and molecular genetics. We ... and have discovered novel genetic breast cancer drivers (Cancer Discovery 2017). We recently uncovered a new stress-induced ...
MOLECULAR CANCER THERAPEUTICS (Journal). Activity: Publication peer-review and editorial work › Publication peer-review ... Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the beta GBP Cytokine, a Physiological PI3K ... TAO kinases using a new inhibitor compound delays mitosis and induces mitotic cell death in centrosome amplified breast cancer ...
  • Approximately 90 % of the recurrences of cancers after the primary general therapy (endocrine as well as chemical) are caused by the genes coding for multiple drug resistance (MDR) [2- (
  • In 2012, the actual figures for 40 European countries were 3.45 million new registered cases of various cancers and 1.75 million deaths from malignancies. (
  • However, despite much investment few targeted therapeutics have successfully progressed to early clinical trials, indicating yet again that the human body is complicated and that much more understanding of the fundamentals of receptor interactions, physics of nanomedical constructs and their circulation in the body is indeed needed. (
  • you want to study the molecular pathology, biology and therapeutics of cancer at an advanced level and develop a dynamic career in biological research or continue with further postgraduate study. (
  • By the end of the course you'll be equipped with a thorough knowledge of cancer biology and pathology, research methodologies, drug development, and regulatory issues. (
  • Methods and analysis: Archival pathology laboratory samples from patients with treatment-refractory advanced solid cancer of any histologic type undergo molecular tumour profiling. (
  • aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Diagnostic Laboratory Techniques, Pathology and Molecular Medicine. (
  • Also, high quality research contributions describing original and unpublished results of conceptual, constructive, empirical, experimental, or theoretical work in all areas of Diagnostic Laboratory Techniques, Pathology and Molecular Medicine are cordially invited for presentation at the conference. (
  • ICDLTPMM 2020 has teamed up with the Special Journal Issue on Diagnostic Laboratory Techniques, Pathology and Molecular Medicine . (
  • An update on Access' ongoing ProLindac Phase 2 clinical study will be presented during Poster Session A, "Clinical Trials" in Abstract #A145 entitled "AP5346, a pH-dependent polymer-vectorized DACH, is safe at pharmacodynamically active doses: Results from an ongoing phase II trial in borderline potentially platinum-sensitive ovarian cancer (OC) patients" on Tuesday, October 23, 2007 from 12:30 p.m. (
  • Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. (
  • Newswise - Postmenopausal women who regularly use aspirin and other analgesics (known as painkillers) have lower estrogen levels, which could contribute to a decreased risk of breast or ovarian cancer. (
  • Gates agreed and said that additional research, like a randomized trial of NSAID use and hormone levels, is needed to confirm these results and to determine whether the decrease in hormone levels translates to a reduced risk of breast or ovarian cancer. (
  • If an inverse association between analgesic use and risk of breast or ovarian cancer is confirmed, then this research may have important public health implications. (
  • Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. (
  • DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. (
  • The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. (
  • Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. (
  • Screening for ovarian cancer: imaging challenges and opportunities for improvement. (
  • Since VEGF-A and its blockade with bevacizumab also play a major role in other cancers, such as ovarian cancer and breast cancer, VEGF-B could also serve as a new predictive biomarker and a target for new drugs for these cancers as well. (
  • This module will provide an understanding of population-based studies and methodology used in cancer epidemiology, focusing on the value of these approaches in cancer prevention and in the design and evaluation of screening programmes. (
  • Michael J. Thun, M.D., M.S., vice president emeritus of epidemiology and surveillance research at the American Cancer Society, said the question of whether regular use of aspirin and other NSAIDs is causally related to reduced breast cancer risk is important, but still unresolved. (
  • Cancer Molecular Targets and Therapeutics is a specialty section of Frontiers in Oncology and Frontiers in Pharmacology. (
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. (
  • The Urologic Oncology Branch conducts clinical and basic research designed to develop better methods for detecting, preventing, and treating patients with kidney cancer , prostate cancer and bladder cancer . (
  • Our oncology nurses and practitioners understand both the genetic basis of prostate and urologic cancers and the rationale behind emerging clinical trials. (
  • This webinar, Part 1 of the "Advances in RNA-based Biomarker Development for Precision Oncology" webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success. (
  • Pancreatic neuroendocrine tumors--pancreatic NETs, pNETs or islet cell tumors--are tumors that form from the abnormal growth of neuroendocrine cells in the pancreas," says lead author Hala Elnakat Thomas, PhD, research assistant professor in the Division of Hematology and Oncology, Department of Internal Medicine, and member of the Cincinnati Cancer Consortium and UC Cancer Institute's Pancreatic Cancer Center. (
  • This is encouraging information for these women, who represent approximately 60 percent of the advanced breast cancer population," said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. (
  • He also is a professor of Oncology, Ophthalmology, and Biomedical Engineering and co-leads the Brain Cancer Program for the Johns Hopkins Kimmel Cancer Center. (
  • He also serves as Head, Pancreatic Cancer Research Program in Phoenix, Arizona, and is Chief Scientific Officer for US Oncology. (
  • Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. (
  • [57-Presently, medical cannabis use is prevalent among patients with various types of cancer, though many say that they "desire but are not receiving information about cannabis use during their treatment from oncology providers. (
  • In a study led by Dipanjan Pan, an Illinois professor of bioengineering, researchers designed nanoparticles that specifically bind to a protein that marks the surface of breast cancer stem cells. (
  • The researchers also saw a significant decrease in overall cancer cell growth, both in the cell cultures and in the mice. (
  • This work also is important to future researchers working in the field of cancer stem cells," said postdoctoral researcher Santosh Misra, the first author of the study. (
  • PHILADELPHIA -- Researchers have linked a structural protein called nestin to a particularly deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better treatment. (
  • PHILADELPHIA - A strong skeleton is less likely to be penetrated by metastasizing cancer cells, so a fortified glass of milk might be the way to block cancer's spread, according to researchers at the ANZAC Research Institute in Concord, Australia. (
  • Using a mouse model of breast cancer metastasis, the researchers found that a calcium deficiency may increase the tendency of advanced breast cancer to target bone. (
  • After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D. (
  • Successful outcomes for surgery to treat early stage lung cancer appear to depend on the level of vitamin D present in a patient - a calculation that includes food sources, supplements, as well as the season of the year during which the operation is performed, according to researchers at Harvard School of Public Health and Harvard Medical School. (
  • The mechanism behind the link between vitamin D and surgery outcome is not known, and the study needs to be validated, the researchers say, but they add that a number of other studies have hinted that vitamin D may work to inhibit a variety of different cancers . (
  • For disease free survival, the researchers found that patients who had operations in winter were about 40 percent more likely to die from their cancer, than patients who had surgery in summer. (
  • The Cancer Theme brings together researchers (including clinicians, clinician-scientists and scientists) from across UCL who are tackling all aspects of cancer laboratory and clinical research. (
  • Below is the link to a list of researchers who are currently working in the field of cancer research at UCL. (
  • Twist, the basic helix-loop-helix transcription factor, is involved in the process of epithelial to mesenchymal transitions (EMTs), which play an essential role in cancer metastasis. (
  • When it is invasive, this cancer affects the deeper tissues of the cervix and may have spread to other parts of the body (metastasis), most notably the lungs, liver, bladder, vagina, and rectum. (
  • The exploitation of these phosphorylation events for diagnostic and therapeutic intervention in cancer treatment has been a rapidly developing area over the last few years. (
  • Despite the deal, though, Indi Molecular has shifted its focus from developing PCCs as research and diagnostic tools to therapeutics, CEO Albert Luderer told GenomeWeb. (
  • To provide an understanding of the principles band practice of molecular diagnosis in the detection and management of disease - To provide an understanding of quality assurance issues in the diagnostic setting - To give examples of the use of current molecular techniques in the management of disease - To provide practical experience of molecular techniques. (
  • If it is indeed specific to regenerative cells, then it will make for an excellent diagnostic tool for a cancer of regenerative mammary cells. (
  • Bringing together more than 150 experts from industry, research laboratories, hospitals, device and diagnostic manufacturers and academia in the field of cancer research, the congress will be an excellent opportunity to meet and network with industry peers and share experiences. (
  • The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services. (
  • Sahlin P, Windh P, Lauritzen C, Emanuelsson M, Grönberg H, Stenman G. Women with Saethre-Chotzen syndrome are at increased risk of breast cancer. (
  • Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. (
  • Breast Cancer Res Treat. (
  • Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. (
  • TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells. (
  • Abnormal Hedgehog (Hh) pathway activity has been reported in many cancers including basal cell carcinomas, medulloblastomas, rhabdomyosarcomas, glioblastomas, breast and prostate cancers. (
  • In a recent study, we applied high-resolution microarray-based aCGH analysis to FFPE breast cancer samples. (
  • Patients with this type of breast cancer are at high risk for recurrence," said James DiRenzo, Ph.D., assistant professor at Dartmouth Medical School. (
  • The basal epithelial breast cancer subtype represents 17 to 37 percent of all breast cancers and is more common in premenopausal African American women than in other demographic groups. (
  • Among breast cancers, this subtype is known to have an early age of onset and a very short time between treatment and relapse. (
  • These important clinical correlations likely explain why this subtype disproportionately accounts for breast cancer mortality, according to DiRenzo. (
  • The study was funded by the National Cancer Institute, the U.S. Department of Defense Breast Cancer Research Program and the Mary Kay Ash Charitable Foundation. (
  • According to Dunstan, his results call for further, directed clinical trials "to investigate how calcium and vitamin D status influence progression to metastatic disease, and to determine if corrections of calcium and vitamin D deficiencies are important in breast cancer patients. (
  • While many patients with HER2-positive breast cancer respond to trastuzumab, a subset of patients do not. (
  • Additionally, the authors found that elevated WBP2 expression augmented trastuzumab treatment response in a variety of preclinical models, suggesting that WBP2 expression is a potential biomarker for response to trastuzumab treatment in patients with HER2-positive breast cancer. (
  • Pfizer Inc. (NYSE:PFE) today announced that the randomized Phase 2 trial [PALOMA-of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer. (
  • We are delighted with the final data, which suggest the potential for palbociclib to transform the standard of care for post-menopausal women with ER+ and HER2- advanced breast cancer. (
  • PALOMA-1 (also known as Study 1003) is a Phase 2 trial designed to assess the PFS of palbociclib (125 mg once daily for three out of four weeks in repeated cycles) in combination with letrozole versus letrozole alone (2.5 mg once daily on a continuous regimen) in post-menopausal women with ER+, HER2- advanced breast cancer. (
  • Pfizer has worked closely with investigators and international breast cancer experts to establish a robust development program for palbociclib in ER+, HER2- breast cancer across stages and treatment settings. (
  • Pfizer has initiated two Phase 3 studies of palbociclib in advanced/metastatic breast cancer. (
  • PALOMA-2 (also known as Study 1008) is a randomized (2:1), multi-center, double blind Phase 3 study that evaluates palbociclib in combination with letrozole versus letrozole plus placebo as first-line treatment for post-menopausal patients with ER+, HER2- advanced breast cancer. (
  • Walnut consumption may provide the body with essential omega-3 fatty acids, antioxidants and phytosterols that reduce the risk of breast cancer, according to a study presented at the American Association for Cancer Research 100th Annual Meeting 2009. (
  • It is clear that walnuts contribute to a healthy diet that can reduce breast cancer. (
  • Brufsky and colleagues used data from the registHER study to evaluate the incidence, potential risk factors and outcomes for patients with HER2-positive breast cancer. (
  • Philadelphia, PA (Vocus) September 30, 2009 -- Social environment can play an important role in the biology of disease, including breast cancer, and lead to significant differences in health outcome, according to results of a study published in Cancer Prevention Research , a journal of the American Association for Cancer Research. (
  • Previous results from clinical studies have indicated that social support can improve the health outcome of patients with breast cancer. (
  • Wendi Fox Pedicone became a cancer statistic in August 2004 when she was diagnosed with advanced stage breast cancer. (
  • Toxicological issues prevented long term use of clomifene and further drug development for other potential applications such as breast cancer treatment and prevention. (
  • It was another ten years before tamoxifen was approved in December 1977, not as a contraceptive but as a hormonal treatment to treat and prevent breast cancer. (
  • Toremifene has been shown to be compatible with tamoxifen, and in 1996 it was approved for use in the treatment of breast cancer in postmenopausal women. (
  • Raloxifene originally failed as a breast cancer drug due to its poor performance in comparison to tamoxifen in the laboratory but the estrogenic effects of raloxifene on bone led to its rediscovery and approval in 1997. (
  • It was approved for prevention and treatment of osteoporosis and was the first clinically available SERM to prevent both osteoporosis and breast cancer. (
  • Including treatment of ovulatory dysfunction in the management of infertility, treatment and prevention of postmenopausal osteoporosis, treatment and reduction in risk of breast cancer and treatment of dyspareunia due to menopause. (
  • SERMs are used dependent on their pattern of action in various tissues: Tamoxifen is a first-line hormonal treatment of ER-positive metastatic breast cancer. (
  • It is used for breast cancer risk reduction in women at high risk, and as adjuvant treatment of axillary node-negative and node-positive, ductal carcinoma in situ. (
  • Treatment with the monoclonal antibody bevacizumab, which blockades VEGF-A, inhibits this vascular growth in metastasised colorectal cancer. (
  • The course comprises three months of intensive lectures, tutorials and taught lab work, followed by a further month of advanced topic lectures delivered by scientists at the cutting-edge of translational research, focusing on therapeutics and prevention. (
  • As well as developing your understanding of the processes and techniques used in cancer research, you will learn how to critically analyse research data and research papers and how to communicate complex scientific concepts and processes. (
  • The Cancer Molecular Therapeutics Research Association (CMTRA) was created in 2008 to organize and host the annual Molecular Therapeutics of Cancer Research meeting. (
  • To draw greater attention to the opportunities afforded by innovative research in PTMs, a 2-day workshop was conducted August 2002 in Bethesda, MD. The goals of this meeting were to address several topics where PTMs play roles in cancer progression, consider what technologies can be applied to clinical prevention or detection of cancer, and assess what PTMs could be pursued for development of promising surrogate markers. (
  • By providing this overview, it should be apparent that PTMs are key to understanding cancer biology and thus should receive special attention for applications in translational research. (
  • NEW YORK (GenomeWeb) - Indi Molecular this week announced a co-development deal with Sigma-Aldrich to explore use of its PCC (protein catalyzed capture) agent technology in Sigma-Aldrich's line of protein research reagents. (
  • Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). (
  • This programme gives you the foundation in molecular and cellular biology that is fundamental to cancer biology and research. (
  • This may involve setting up a 'mock' clinical trial to gain experience of clinical research and drug development in the cancer setting. (
  • This programme is delivered by the Barts Cancer Institute, a Cancer Research UK centre of excellence and part of the Cancer Research UK City of London Centre . (
  • Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics , entitled, " Sprague Dawley Rag2 -null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts . (
  • American Association for Cancer Research (AACR) journal, Sprague Dawley Rag2 -null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. (
  • Wagner specializes in research and treatment of children with cancer. (
  • Committed to providing the highest quality care based on cutting edge research to patients with cancer or non-malignant hematologic diseases such as sickle cell disease. (
  • The mission of the American Association for Cancer Research is to prevent and cure cancer. (
  • Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. (
  • Their findings are presented in the Oct. 1 issue of Cancer Research, a journal of the American Association for Cancer Research. (
  • It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy. (
  • Their results were reported here today at the 96th Annual Meeting of the American Association for Cancer Research. (
  • To gauge susceptibility for prostate cancer among their research subjects, the team of Italian scientists recruited men with high-grade prostatic intraepithelial neoplasia - premalignant lesions that presage invasive prostate cancer within one year in nearly a third of cases and for which no treatment was given. (
  • Their study, presented here at the 96th Annual Meeting of the American Association for Cancer Research, shows that patients with high vitamin D intake who had surgery in months with lots of sun were more than twice as likely to be alive five years after surgery, compared to patients with low vitamin D intake who had wintertime operations. (
  • Animal studies have shown that treatment of cancer with vitamin D demonstrates both anti-proliferative and anti-invasive properties, but we don\'t know if that is true in humans with cancer,\" says the lead investigator, Wei Zhou, Ph.D., a research scientist at the Harvard School of Public Health. (
  • The research team, led by Prof. David Christiani, M.D., of Harvard University, included investigators from Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women\'s Hospital and Harvard Medical School, looked at the disease free survival (DFS) and overall survival (OS) in 456 patients with early stage non-small cell lung cancer. (
  • The authors represent the premier cancer research center in Canada. (
  • PHILADELPHIA - The next cancer-fighting therapeutic could be growing in your garden, according to research presented today, at the American Association for Cancer Research s Sixth Annual International Conference on Frontiers in Cancer Prevention Research, being held from December 5 to 8 in Philadelphia, Pennsylvania. (
  • As a regular feature on this blog, we spotlight 10 "must read" articles selected by our editors from each journal issue published by the American Association for Cancer Research (AACR). (
  • The AACR s most recent publication and its sixth major journal, Cancer Prevention Research, is dedicated exclusively to cancer prevention, from preclinical research to clinical trials. (
  • Detailed efficacy and safety data from PALOMA-1 will be submitted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 scheduled for April 5-9 thin San Diego. (
  • PALOMA-1 was conducted in collaboration with the Jonsson Cancer Center's Revlon/UCLA Women's Cancer Research Program. (
  • We actively collaborate with other research groups within Drexel University College of Medicine, and at Howard Hughes Medical Institute at the University of Maryland, University of Pennsylvania, Johns Hopkins University, Dana Farber Cancer Institute (Harvard University) and the Southern Research Institute. (
  • The Department of Data Science in collaboration with the Computational Biology and Chemogenomics team in the CRUK Cancer Therapeutics Unit at The Institute of Cancer Research , London. (
  • canSAR is funded by the Cancer Research UK Drug Discovery Committee strategic award 'canSAR: enhancing the drug discovery knowledgebase' C35696/A23187. (
  • canSAR: update to the cancer translational research and drug discovery knowledgebase , Coker EA et al, Nucl. (
  • St. Jude Children s Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. (
  • More recent research suggests that the involvement of glutamine in cancer metabolism is more significant than previously thought. (
  • The American Association for Cancer Research hosted a press briefin. (
  • The American Association for Cancer Research hosted a press briefing on this study on September 29 at 1:00 p.m. (
  • Read the full Cancer Prevention Research study . (
  • She then moved to the Beatson Institute for Cancer Research as a post-doc with Prof Margaret Frame where she worked on the role of the non-receptor tyrosine kinases Src and FAK in tumour cell progression. (
  • The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, biomedical sciences, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. (
  • I am a dermato-oncologist with a focus and specific expertise in cellular signalling in skin biology and cancer, committed to the delivery of high quality translational research, education and teaching. (
  • Cancer Research , 74 , . (
  • YELIVA™ (ABC294640) is a Phase II-stage, proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with anti-cancer and anti-inflammatory activities. (
  • For the past month, articles span from a preclinical study of a selective HER-2 inhibitor to a report on the prevalence of cancer risk factors and screening rates in the United States. (
  • Lung cancer is a deadly disease that is difficult to diagnose and even more difficult to treat effectively. (
  • These receptors are expressed in many normal and malignant cells, including both small cell and non-small cell lung cancer. (
  • Synthetic analogs of SSTRs are commercially available, but their effects in lung cancer are still largely uncertain. (
  • Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. (
  • One of the greatest challenges after the discovery of cancer specific targets is to decipher the complexity of the targetable protein function and to develop innovative target-only drugs which selectively fight cancer but not normal cells. (
  • Your download Molecular Cancer Therapeutics: Strategies for Drug Discovery has published a Awesome or due organization. (
  • offers who are bleaching for a more download Molecular Cancer Therapeutics: Strategies for Drug Discovery and jet can align the image community past the experience to a search and a new village. (
  • Meg Whitman a empty download Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development 2004 in California was embarked running a have evolved out by her neuroscience j that left a YouTube rate of a 18th-century oppositio. (
  • He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. (
  • Since the discovery of the Warburg effect, it has been shown that the metabolism of cancer cells plays a critical role in cancer survival and growth. (
  • DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors. (
  • Progress in Vaccination Against Cancer (PIVAC) aims to bring together translational and clinical oncologists and immunologists dealing with active vaccination against cancer for three days of presentations on the most recent advances in the field. (
  • Topics covered include: - The major environmental causes of cancer and their contribution to cancer worldwide - The potential for reducing cancer incidence - The role of screening in cancer control - The prospects for the chemoprevention of cancer in the next ten years. (
  • This article outlines the prevalence of modifiable cancer risk factors, screening utilization, and vaccination rates in the U.S. adult population. (
  • 2004. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets . (
  • The Peter MacCallum Cancer Centre acknowledges the traditional owners of the land on which our five sites are located throughout Victoria. (
  • The first treatment trials will focus on RLT for men with incurable, metastatic prostate cancer. (
  • The Branch also has an expanding prostate cancer program. (
  • Bettuzzi and his colleagues had found that EGCG targets prostate cancer cells specifically for death, without damaging the benign controls. (
  • Only one case of prostate cancer was diagnosed among those receiving 600 mg daily of GTCs, while nine cases were found in the untreated group. (
  • Bettuzzi observed that the Mediterranean diet is rich in vegetables, and lower rates of prostate cancer are found in that region, as well. (
  • We still don't know enough about the biological processes leading to prostate cancer," Bettuzzi noted. (
  • The only thing we know for sure is that prostate cancer is diffuse, related to age and more prevalent in the West. (
  • and a new berry-rich beverage, made from a combination of known plant-based antioxidants, could prevent or slow the growth of prostate cancer. (
  • Four of six critically ill COVID-19 (coronavirus) patients significantly improved after receiving an experimental therapeutic designed to reduce inflammation, a major cause of death from this disease, according to a case series published by Cedars-Sinai and Capricor Therapeutics. (
  • For this reason the Hh pathway is a flourishing area for development of anti-cancer drugs such as Hh ligand antagonists (e.g. 5E1, robotnikinin), Smo inhibitors (e.g. (
  • Such findings can be of great value in designing clinical trials of new cancer drugs as well as in optimizing the clinical benefit of approved drugs. (
  • He and his colleagues were involved in the early development of drugs that are now routinely used to treat cancer, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. (
  • The development of effective immunotherapies, vaccines and immunomodulatory drugs are the main success stories from the last years in drugs development for cancer, infectious diseases and chronic disorders. (
  • Basic discussion of scientific techniques will include: recombinant protein production and purification, DNA and RNA purification and methods, molecular biology methods, microscopy, and an introduction to basic model systems and bioinformatics. (
  • It provides a single information portal to answer complex multi-disciplinary questions including - among many others: what is known about a protein, in which cancers is it expressed or mutated and what chemical tools and cell line models can be used to experimentally probe its activity? (
  • Adverse effects include hot flushes and more serious is two to three times higher relative risk of developing endometrial cancer compared to women of an age-matched population. (
  • We also welcome applicants with significant relevant industrial or professional experience, and medically qualified applicants with a strong background in molecular biology and/or cell biology. (